125 related articles for article (PubMed ID: 8110560)
1. Viability criterion of muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases.
Adnet PJ; Krivosic-Horber RM; Krivosic I; Haudecoeur G; Reyford HG; Adamantidis MM; Medahoui H
Br J Anaesth; 1994 Jan; 72(1):93-7. PubMed ID: 8110560
[TBL] [Abstract][Full Text] [Related]
2. In vitro contracture tests in patients with various neuromuscular diseases.
Heytens L; Martin JJ; Van de Kelft E; Bossaert LL
Br J Anaesth; 1992 Jan; 68(1):72-5. PubMed ID: 1739572
[TBL] [Abstract][Full Text] [Related]
3. Halothane-caffeine contracture testing in neuromuscular diseases.
Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
5. Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test?
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyford HG; Dupuis BA
Anesth Analg; 1992 Jan; 74(1):105-11. PubMed ID: 1734769
[TBL] [Abstract][Full Text] [Related]
6. Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia?
Lehmann-Horn F; Iaizzo PA
Br J Anaesth; 1990 Nov; 65(5):692-7. PubMed ID: 2248848
[TBL] [Abstract][Full Text] [Related]
7. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
8. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
9. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
10. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
[TBL] [Abstract][Full Text] [Related]
11. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ
Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436
[TBL] [Abstract][Full Text] [Related]
12. Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro.
Ilias WK; Williams CH; Fulfer RT; Dozier SE
Br J Anaesth; 1985 Oct; 57(10):994-6. PubMed ID: 4041327
[TBL] [Abstract][Full Text] [Related]
13. Effects of midazolam on directly stimulated muscle biopsies from control and malignant hyperthermia positive patients.
Fletcher JE; Rosenberg H; Hilf M
Can Anaesth Soc J; 1984 Jul; 31(4):377-81. PubMed ID: 6146391
[TBL] [Abstract][Full Text] [Related]
14. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
15. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
Allen GC; Larach MG; Kunselman AR
Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
[TBL] [Abstract][Full Text] [Related]
16. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
[TBL] [Abstract][Full Text] [Related]
17. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
18. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
Nelson TE; Bedell DM; Jones EW
Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
[TBL] [Abstract][Full Text] [Related]
19. The in vitro determination of susceptibility to malignant hyperthermia.
Iaizzo PA; Lehmann-Horn F
Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
[TBL] [Abstract][Full Text] [Related]
20. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Adamantidis MM; Reyford GH; Imbenotte M; Cordonnier C
Br J Anaesth; 1990 Dec; 65(6):791-5. PubMed ID: 1702303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
